Head-To-Head Analysis: 10x Genomics (TXG) & The Competition

10x Genomics (NASDAQ:TXG) is one of 109 publicly-traded companies in the “Life Sciences Tools & Services” industry, but how does it compare to its rivals? We will compare 10x Genomics to related businesses based on the strength of its analyst recommendations, profitability, earnings, institutional ownership, valuation, dividends and risk.

Profitability

This table compares 10x Genomics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
10x Genomics	-12.18%	-9.33%	-7.30%
10x Genomics Competitors	-540.60%	-166.50%	-13.58%

Valuation & Earnings

This table compares 10x Genomics and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
10x Genomics	$642.82 million	-$43.54 million	-100.34
10x Genomics Competitors	$2.29 billion	$55.88 billion	-13.59

10x Genomics’ rivals have higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings and recommmendations for 10x Genomics and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1	12	5	0	2.22
10x Genomics Competitors	948	3170	5495	178	2.50

10x Genomics currently has a consensus price target of $68.00, suggesting a potential upside of 14.86%. As a group, “Life Sciences Tools & Services” companies have a potential downside of 1.27%. Given 10x Genomics’ higher possible upside, equities analysts plainly believe 10x Genomics is more favorable than its rivals.

Insider and Institutional Ownership

84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 53.7% of shares of all “Life Sciences Tools & Services” companies are held by institutional investors. 8.8% of 10x Genomics shares are held by company insiders. Comparatively, 15.0% of shares of all “Life Sciences Tools & Services” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

10x Genomics has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500. Comparatively, 10x Genomics’ rivals have a beta of 1.15, meaning that their average share price is 15% more volatile than the S&P 500.

Summary

10x Genomics rivals beat 10x Genomics on 7 of the 13 factors compared.

About 10x Genomics

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.